Alkem Laboratories share price rose in the opening trade on February 5 after the company launched Kojiglo serum in India for managing facial hyperpigmentation, which is suitable for all skin types.
At 09:29am, Alkem Laboratories was quoting at Rs 5,162.25, up Rs 55.00, or 1.08 percent, on the BSE.
The company is the first Indian company to introduce a liposomal serum with Duo-Lipo technology.
This innovative formulation combines cutting-edge ingredients such as liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide, making it a first of its kind in India to have a Duo-Lipo technology, it added.
This advanced serum encapsulates the active ingredients in a liposomal form to enhance penetration in the skin and deliver targeted action, company said.
Catch all the market action on our live blog
A meeting of the board of directors of the company is scheduled to be held on February 7, 2025, to consider and approve the standalone and consolidated unaudited financial results of the company for the quarter and nine months ended 31st December, 2024.
The board will also consider and approve interim dividend for financial year 2024-2025.
The company had set February 14 as a record date for the purpose of payment of interim dividend for financial year 2024-2025, subject to declaration.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
